Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database
Tóm tắt
Invasive micropapillary carcinoma (IMPC) is an uncommon subtype of breast cancer. Previous studies of this subtype demonstrated a higher propensity for lymph node metastases as compared with invasive ductal carcinoma (IDC). The purpose of the present study was to determine the clinical characteristics, outcomes, and propensity for lymph node metastasis of patients with IMPC of the breast recorded in the National Cancer Database (NCDB). Records of patients with IMPC diagnosed between 2004 and 2014 were retrieved from the NCDB. Log-rank test was performed to evaluate associations of clinical characteristics with overall survival (OS). Cox proportional hazards model was used to determine variables associated with OS. Overall, 2660 patients with IMPC met the selection criteria; the 5-year OS rate was 87.5% and 24.9% of patients had nodal involvement at presentation. Patients with ≥ 4 positive lymph nodes had shorter OS than node-negative patients, whereas patients with 1–3 positive nodes had similar OS to node-negative patients. Age < 65 years, receipt of radiotherapy, and estrogen receptor positivity were also associated with prolonged OS. The benefit of radiotherapy was limited to IMPC patients undergoing lumpectomy; there was no benefit for the patients undergoing mastectomy (regardless of nodal positivity/negativity). Favorable prognostic factors of IMPC patients included age < 65 years, < 4 positive lymph nodes, receipt of radiotherapy, and estrogen receptor positivity. The results presented herein suggest a survival benefit associated with radiotherapy in IMPC treatment, though this may be limited to the patients treated with lumpectomy.
Tài liệu tham khảo
Fisher ER, Palekar AS, Redmond C, Barton B, Fisher B. Pathologic Findings from the National Surgical Adjuvant Breast Project (Protocol No. 4): VI. Invasive papillary cancer. Am J Clin Pathol. 1980;73(3):313–22. https://doi.org/10.1093/ajcp/73.3.313.
Kim MJ, Gong G, Joo HJ, Ahn SH, Ro JY. Immunohistochemical and clinicopathologic characteristics of invasive ductal carcinoma of breast with micropapillary carcinoma component. Arch Pathol Lab Med. 2005;129(10):1277–82.
Chen AC, Paulino AC, Schwartz MR, Rodriguez AA, Bass BL, Chang JC, et al. Prognostic markers for invasive micropapillary carcinoma of the breast: a population-based analysis. Clin Breast Cancer. 2013;13(2):133–9.
Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. New York: IARC; 2003.
Yu JI, Choi DH, Huh SJ, Cho EY, Kim K, Chie EK, et al. Differences in prognostic factors and failure patterns between invasive micropapillary carcinoma and carcinoma with micropapillary component versus invasive ductal carcinoma of the breast: retrospective multicenter case–control study (KROG 13-06). Clin Breast Cancer. 2015;15(5):352–3.
Chen H, Ding A. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast. Breast. 2015;24(6):723–31.
Shi WB, Yang LJ, Hu X, Zhou J, Zhang Q, Shao ZM. Clinico-pathological features and prognosis of invasive micropapillary carcinoma compared to invasive ductal carcinoma: a population-based study from China. PLoS ONE. 2014;9(6):e101390.
Cui ZQ, Feng JH, Zhao YJ. Clinicopathological features of invasive micropapillary carcinoma of the breast. Oncol Lett. 2015;9(3):1163–6. https://doi.org/10.3892/ol.2014.2806.
Lerro CC, Robbins AS, Phillips JL, Stewart AK. Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann Surg Oncol. 2013;20(6):1759–65. https://doi.org/10.1245/s10434-013-2901-1.
Haque W, Lewis GD, Verma V, Darcourt JG, Butler EB, Teh BS. The role of adjuvant chemotherapy in locally advanced bladder cancer. Acta Oncol (Madr). 2018;57(4):509–15. https://doi.org/10.1080/0284186X.2017.1415461.
Haque W, Verma V, Lewis GD, Lo SS, Butler EB, Teh BS. Utilization of radiotherapy and stereotactic body radiation therapy for renal cell cancer in the USA. Future Oncol. 2018;14(9):819–27. https://doi.org/10.2217/fon-2017-0536.
Lewis GD, Haque W, Butler EB, Teh BS. Survival outcomes and patterns of management for anal adenocarcinoma. Ann Surg Oncol. 2019;26(5):1351–7. https://doi.org/10.1245/s10434-019-07202-4.
Lewis GD, Dalwadi SM, Farach A, Butler EB, Teh BS. The role of adjuvant radiotherapy in the treatment of pleural mesothelioma. Ann Surg Oncol. 2019;26(6):1879–85. https://doi.org/10.1245/s10434-019-07235-9.
Lewis GD, Haque W, Verma V, Butler EB, Teh BS. The role of adjuvant radiation therapy in locally advanced bladder cancer. Bl Cancer. 2018;4(2):205–13.
Chen AC, Paulino AC, Schwartz MR, Rodriguez AA, Bass BL, Chang JC, et al. Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast. Br J Cancer. 2014;111(3):619–22.
Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984;2(10):1102–9.
Osborne CK, Fisher E, Redmond C, Knight WA, Yochmowitz MG, McGuire WL. Estrogen receptor, a marker for human breast cancer differentiation and patient prognosis. Boston: Springer; 1982. p. 377–85. https://doi.org/10.1007/978-1-4615-7192-6_23.
Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26(14):2373–8. https://doi.org/10.1200/JCO.2007.14.4287.
Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24(36):5652–7.
Zuo T, Zeng H, Li H, Liu S, Yang L, Xia C, et al. The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study. Chin J Cancer. 2017;36(1):84.
de la Rochefordière A, Campana F, Fenton J, Vilcoq JR, Fourquet A, Asselain B, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet. 1993;341(8852):1039–43.
Fredholm H, Magnusson K, Lindström LS, Garmo H, Fält SE, Lindman H, et al. Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Res Treat. 2016;160(1):131–43. https://doi.org/10.1007/s10549-016-3983-9.
Wong FY, Tham WY, Nei WL, Lim C, Miao H. Age exerts a continuous effect in the outcomes of Asian breast cancer patients treated with breast-conserving therapy. Cancer Commun (London, England). 2018;38(1):39.
Bonnier P, Romain S, Charpin C, Lejeune C, Tubiana N, Martin P-M, et al. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer. 1995;62(2):138–44. https://doi.org/10.1002/ijc.2910620205.
Sabiani L, Houvenaeghel G, Heinemann M, Reyal F, Classe JM, Cohen M, et al. Breast cancer in young women: pathologic features and molecular phenotype. Breast. 2016;29:109–16.
Liedtke C, Rody A, Gluz O, Baumann K, Beyer D, Kohls E-B, et al. The prognostic impact of age in different molecular subtypes of breast cancer. Breast Cancer Res Treat. 2015;152(3):667–73. https://doi.org/10.1007/s10549-015-3491-3.
Griffiths RI, Gleeson ML, Valderas JM, Danese MD. Impact of undetected comorbidity on treatment and outcomes of breast cancer. Int J Breast Cancer. 2014;2014:970780.
Braithwaite D, Moore DH, Satariano WA, Kwan ML, Hiatt RA, Kroenke C, et al. Prognostic impact of comorbidity among long-term breast cancer survivors: results from the LACE study. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1115–25.
Land LH, Dalton SO, Jørgensen TL, Ewertz M. Comorbidity and survival after early breast cancer: a review. Crit Rev Oncol Hematol. 2012;81(2):196–205.
Clarke M, Collins R, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.
Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82(3):247–53.
Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. JNCI J Natl Cancer Inst. 2005;97(2):116–26. https://doi.org/10.1093/jnci/djh297.
Haffty BG, Mahmoud O. The evolution of regional nodal irradiation in breast cancer. Breast J. 2015;21(1):32–41. https://doi.org/10.1111/tbj.12351.
Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307–16. https://doi.org/10.1056/NEJMoa1415340.
Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317–27. https://doi.org/10.1056/NEJMoa1415369.
EBCTCG (Early Breast Cancer Trialists’ Collaborative Group) P, McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet (London, England). 2014;383(9935):2127–35.
Walsh MM, Bleiweiss IJ. Invasive micropapillary carcinoma of the breast: eighty cases of an underrecognized entity. Hum Pathol. 2001;32(6):583–9.
Vingiani A, Maisonneuve P, Dell’Orto P, Farante G, Rotmensz N, Lissidini G, et al. The clinical relevance of micropapillary carcinoma of the breast: a case–control study. Histopathology. 2013;63(2):217–24. https://doi.org/10.1111/his.12147.
Adrada B, Arribas E, Gilcrease M, Yang WT. Invasive micropapillary carcinoma of the breast: mammographic, sonographic, and MRI features. Am J Roentgenol. 2009;193(1):W58–63. https://doi.org/10.2214/AJR.08.1537.
Chen L, Fan Y, Lang R, Guo X, Sun Y, Cui L, et al. Breast carcinoma with micropapillary features: clinicopathologic study and long-term follow-up of 100 cases. Int J Surg Pathol. 2008;16(2):155–63. https://doi.org/10.1177/1066896907307047.
De La Cruz C, Moriya T, Endoh M, Watanabe M, Takeyama J, Yang M, et al. Invasive micropapillary carcinoma of the breast: clinicopathological and immunohistochemical study. Pathol Int. 2004;54(2):90–6. https://doi.org/10.1111/j.1440-1827.2004.01590.x.
Luna-Moré S, Casquero S, Pérez-Mellado A, Rius F, Weill B, Gornemann I. Importance of estrogen receptors for the behavior of invasive micropapillary carcinoma of the breast. Review of 68 cases with follow-up of 54. Pathol Res Pract. 2000;196(1):35–9.
Middleton LP, Tressera F, Sobel ME, Bryant BR, Alburquerque A, Grases P, et al. Infiltrating micropapillary carcinoma of the breast. Mod Pathol. 1999;12(5):499–504.
Nassar H, Wallis T, Andea A, Dey J, Adsay V, Visscher D. Clinicopathologic analysis of invasive micropapillary differentiation in breast carcinoma. Mod Pathol. 2001;14(9):836–41.
Paterakos M, Watkin WG, Edgerton SM, Moore DH, Thor AD. Invasive micropapillary carcinoma of the breast: a prognostic study. Hum Pathol. 1999;30(12):1459–63.
Pettinato G, Manivel CJ, Panico L, Sparano L, Petrella G. Invasive micropapillary carcinoma of the breast. Am J Clin Pathol. 2004;121(6):857–66. https://doi.org/10.1309/XTJ7VHB49UD78X60.
Yamaguchi R, Tanaka M, Kondo K, Yokoyama T, Kaneko Y, Yamaguchi M, et al. Characteristic morphology of invasive micropapillary carcinoma of the breast: an immunohistochemical analysis. Jpn J Clin Oncol. 2010;40(8):781–7.
Zekioglu O, Erhan Y, Ciris M, Bayramoglu H, Ozdemir N. Invasive micropapillary carcinoma of the breast: high incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma. Histopathology. 2004;44(1):18–23. https://doi.org/10.1111/j.1365-2559.2004.01757.x.